SCARB1 Genotype

Two people can have similar HDL numbers and very different underlying biology. SCARB1 (scavenger receptor class B type I) is one of the reasons why. This gene tells your cells how to build the main doorway that pulls cholesterol out of HDL particles, and inherited variations in this doorway can quietly shape your lipid profile, your heart disease risk, and even how your body responds to certain treatments.

Testing your SCARB1 genotype gives you a one-time snapshot of inherited variation that standard cholesterol panels cannot see. It is an emerging research marker, not a routine clinical test, but for people with unusual lipid patterns, premature heart disease, or a strong family history, the result can add useful context to decisions made over a lifetime.

What the SCARB1 Gene Does

SCARB1 encodes a protein called SR-BI (scavenger receptor class B type I) that sits on the surface of cells in the liver, adrenal glands, and other tissues. SR-BI grabs cholesterol from circulating HDL particles and pulls it into cells for use or disposal. When inherited variations change how much SR-BI your cells make, or how well the protein works, the downstream ripple touches HDL levels, other lipid traits, and patterns of artery disease.

Different SCARB1 variants do different things. Some sit in the promoter region (the on-switch that controls how much SR-BI is produced). Others change the protein itself. Still others are common letter swaps in non-coding regions that subtly tune expression. Because the variants are not interchangeable, the clinical meaning of a SCARB1 result depends on which specific variant you carry.

Heart Disease and Heart Attack Risk

Several SCARB1 variants have been linked to coronary heart disease in human studies. Two promoter variants (rs144334493 and rs557348251) were associated with both abnormal lipid profiles and higher coronary heart disease risk, with evidence that they shift how much SR-BI your cells produce. A common missense variant (rs4238001, also known as Gly2Ser) was statistically associated with new cases of coronary heart disease across a multi-ethnic population, with stronger effects in men.

A non-coding (intronic) variant called rs10846744 has been one of the most consistently reported. In the Multi-Ethnic Study of Atherosclerosis, it was tied to subclinical atherosclerosis (early artery thickening) and to incident cardiovascular events. The same variant was also linked in a meta-analysis to higher Lp-PLA2 activity (a marker associated with vascular inflammation and plaque vulnerability) and to coronary artery disease events in the CARDIoGRAMplusC4D consortium, although Lp-PLA2 activity did not turn out to be a confirmed mediator of the rs10846744 effect on atherosclerosis after adjustment for cardiovascular risk factors.

Another commonly studied variant, rs5888, appears to change risk in an age- and sex-dependent way. In one large analysis, the TT genotype was linked to lower odds of heart attack in men aged 65 to 75. In a separate case-control study of premature coronary artery disease, the T allele was associated with higher odds of disease in women. A subsequent meta-analysis of rs5888 and coronary heart disease found only a non-significant trend toward lower CHD risk with the T allele in the overall population, so the strongest signals appear to be in specific age and sex subgroups rather than across the board. The same variant has come up in studies of peripheral arterial disease, where combined SCARB1 genotypes predicted PAD risk with different risk alleles in men versus women.

Why High HDL From SCARB1 Variants Is Not Always Protective

Here is the part that breaks the simple HDL story. Several rare SCARB1 mutations (p.G319V, p.V111M, p.V32M) noticeably raised HDL cholesterol without changing coronary artery disease risk in a large Icelandic study. A different rare variant, P376L, raised HDL but also increased coronary heart disease risk. This is not a paradox. SCARB1 is a phenotype gene, not a good-number-bad-number gene. When SR-BI works poorly, cholesterol gets stuck inside HDL particles instead of being delivered to the liver. HDL rises on the lab report, but the cholesterol-removal pipeline (reverse cholesterol transport) is actually working less well. Whether that translates into more artery disease depends on which specific variant you carry and how severely it impairs SR-BI function.

Other Conditions Linked to SCARB1 Variants

Beyond the heart, SCARB1 variants have been studied in several other contexts. The rs5888 variant has been associated with age-related macular degeneration (AMD) in a candidate gene study, likely because SR-BI also helps transport carotenoids and other antioxidants that protect the eye, though SCARB1 has not emerged as a top locus in the largest AMD genome-wide studies. An intronic variant (rs11057841) was tied to serum lutein concentration, with a 24% increase per copy of the T allele. A SCARB1 variant (rs11057820) has also been linked to papillary thyroid cancer risk in a German replication study, and SCARB1 variants have been linked to insulin resistance, especially in women, with a clear gene-by-sex interaction.

The gene also shows up in treatment-response research. In people with chronic hepatitis C, the rs10846744 genotype predicted sustained virologic response on pegylated interferon plus ribavirin therapy, likely because SR-BI is one of the entry receptors hepatitis C virus uses to infect liver cells. A diet study found that carriers of one exon 1 variant had significantly improved insulin sensitivity after a monounsaturated-fat-rich diet but not after saturated-fat or high-carb diets.

A Once-in-a-Lifetime Test

Your SCARB1 genotype is fixed at conception. The result you get today is the result you would get next year, in a decade, and at any age. Unlike cholesterol or HDL, there is nothing to retest and no trend to track. The value of the test comes from how the result shapes the decisions you make over the rest of your life, especially around how aggressively you monitor and manage your standard lipid markers.

What does benefit from ongoing tracking is the downstream phenotype. If your SCARB1 result points to elevated cardiovascular risk, the actionable response is more frequent lipid panels, ApoB testing, Lp(a), and inflammation markers like hs-CRP (high-sensitivity C-reactive protein) at least annually, plus consideration of coronary calcium imaging at an earlier age than baseline guidelines suggest.

What an Out-of-Pattern Result Should Make You Do

If your SCARB1 result flags a risk-associated variant, the next steps are about workup and stratification, not retesting the gene. Order a full lipid panel including ApoB (apolipoprotein B, a count of artery-damaging particles) and Lp(a) (lipoprotein little a, an inherited cardiovascular risk marker that standard cholesterol testing misses). If your HDL is unusually high or low, that is information rather than reassurance. Combined with a SCARB1 variant, an extreme HDL value warrants a closer look at whether your reverse cholesterol transport pathway is actually working efficiently.

Consider involving a lipidologist or genetic counselor if you carry a rare functional SCARB1 variant, if your standard lipids are extreme in either direction, or if you have a strong family history of premature heart attack, stroke, or unusual cholesterol patterns. For first-degree relatives, the result also matters. Children, siblings, and parents share roughly half of your DNA, so a clinically meaningful SCARB1 variant in you raises the probability they carry it too.

When Genetic Results Can Be Misleading

• Variant panel coverage: SCARB1 testing only detects the specific variants the assay is designed to look for. A result without a flagged variant does not rule out other rare changes in the SCARB1 gene that the panel does not target. Whole-gene sequencing would be needed to be exhaustive.
• Ancestry-specific allele frequencies: Some SCARB1 variants are more common in certain populations than others, and most published studies have been conducted in specific ethnic groups. The clinical meaning of a given result can depend on your ancestry, and effect sizes from one population do not always generalize to another.
• Variants of uncertain significance: Some SCARB1 changes have unclear functional consequences. A reported variant labeled uncertain is not the same as a confirmed risk variant, and acting aggressively on it before more evidence accumulates is rarely warranted.
• Carrying a variant is not the same as developing disease: Most SCARB1 variants modestly shift the odds of disease, often interacting with sex, age, diet, and other genetic factors. Many people who carry a risk variant never develop the associated condition, and many who develop the condition do not carry the variant.